Although currently tailored for binary classification tasks with two data modalities, future iterations will aim to incorporate additional data types, such as neuroimaging and peripheral biomarkers, and expand them to predict disease progression, thereby broadening ADAM-1’s scalability and applicability in AD research and diagnostic applications. This evidence concerns the gene ADAM1A and Alzheimer disease.